iiinova — where your digital self keeps evolving

This link will take you to a page that’s not on LinkedIn

Ultimately, this is what patient-first, clinically anchored I&I discovery looks like. Having model realism we can measure, and targets that come with a built-in reversal readout, ensure well positioned early discovery. ➕✖️

lnkd.in

000

It also shows that RA synovial fluid shifts healthy PBMCs toward the T+B lymphocyte-enriched synovial subtype. Across 1M+ cells, 5 disease backgrounds, & 168 perturbagens, the framework cleanly separates compounds that move donors back toward control from those that push them further into disease. 💡

100

Benchmarked against RA synovium and SLE datasets, our framework recovers known disease axes and gene programs while discovering new morphological endpoints directly from imaging. 📸

100

How accurately do ex vivo models represent real disease states? At #TargetV26, @izepb.bsky.social shared how we’re mapping ex vivo conditions against reference disease atlases using single-cell imaging & transcriptomics to measure their true clinical delta. Full poster here 👉 lnkd.in/d5FVKrup

Graph @graphtx.bsky.social · 14/09/2026

💡 Poster: Quantifying ex vivo model realism for novel target discovery in inflammatory diseases 📍 Wellcome Genome Campus, UK 💬 Presenting author: @izepb.bsky.social

Graph @graphtx.bsky.social · 14/09/2026

🇬🇧 Hinxton, see you 21 - 23 September at the conference Target Validation - In the Era of Genomics, Big Data, and AI! @izepb.bsky.social, Principal Scientist at Graph, will present how we quantify ex vivo model realism and compound reversal for target discovery in inflammatory disease.

Graph @graphtx.bsky.social · 03/07/2026

We’re hiring! 📢 We're looking for a: ➕ Translational Immunologist Validate the key causal drivers behind immune-mediated disease using more realistic biological and computational models. Read more and apply here: www.linkedin.com/jobs/view/44...

linkedin.com

GraphTx hiring Translational Immunologist in Klosterneuburg, Lower Austria, Austria | LinkedIn

Posted 1:19:11 PM. Be at the forefront of AI-driven precision immunology for drug discoverytl;dr: Graph is an…See this and similar jobs on LinkedIn.

Graph @graphtx.bsky.social · 23/06/2026

We're hiring! 📢 ➕ Translational Systems Biologist ➕ Research Data Engineer You’ll join an international team that values participation & collaboration, where you’ll be able to actively shape decisions, culture, & strategy. Apply here ➡️ graph-therapeutics.jobs.personio.com?language=en

💚 A massive thank you to everyone for their support and trust, and most importantly to the innovative and driven team at Graph.

Graph started with a bold mission: to decode complex immune dysfunction for next generation medicines, and now, we are taking a massive leap forward. ➕✖️

100

This milestone marks Graph's official transition from a validated immune disease platform to an internal drug discovery engine. We’re no longer just showing what our lab-in-the-loop AI can do, we're actively advancing our own internal precision therapeutics pipeline to target I&I diseases. 🧩⚙️

100

Graph @graphtx.bsky.social · 30/04/2026

📢 Exciting news! Paris-based VC firm daphni has joined our investor syndicate, leading an additional $5M investment, with continued participation from SquareOne, Merantix Capital, & NAVEC Investment Management. This brings our total funding, including non-dilutive grant support, to over $10M.

140

Ahoj Prague! 🇨🇿 Desy Vallorani, Research Assistant at Graph, will be attending Autoimmunity 2026 from 14 - 17 May! As we continue to decode complex immune dysfunction at scale, we’re looking forward to discussing the latest breakthroughs in inflammatory and immune-mediated diseases. ➕✖️

Graph @graphtx.bsky.social · 27/04/2026

We’re hiring! 📢 We are scaling up our wet lab capabilities and are looking for a Molecular Immunologist to join our team. Consider applying if you are someone who wants to interrogate and validate immune-mediated disease drivers. 🧬🔍🥼 Read the full job description ➡️ lnkd.in/dX6jUgpN

lnkd.in

GraphTx hiring Molecular Immunologist in Klosterneuburg, Lower Austria, Austria | LinkedIn

Posted 1:55:21 PM. Be at the forefront of AI-driven precision immunology for drug discoverytl;dr: Graph is an…See this and similar jobs on LinkedIn.

Graph @graphtx.bsky.social · 23/04/2026

Meet the team behind Graph and say hello to @benhaladik.bsky.social, Scientist! 🧗🛹 With Ben’s help, we’re combining live patient cell models with advanced machine learning to decode complex immune dysfunction, driving our lab-in-the-loop platform. ➕✖️

Graph @graphtx.bsky.social · 20/04/2026

We're hiring! 📢 Our team is looking for a Full Stack Biologist driving research at the interface of computational & lab biology. Consider applying if you want to better understand the causal mechanisms of disease using multi-modal, realistic primary cell models. ⚙️ 🧬 💡 Apply here ➡️ lnkd.in/dBuA73nG

lnkd.in

GraphTx hiring Full Stack Biologist in Klosterneuburg, Lower Austria, Austria | LinkedIn

Posted 6:37:27 AM. Be at the forefront of AI-driven precision immunology for drug discoverytl;dr: Graph is an…See this and similar jobs on LinkedIn.

Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets - My Framer Site

This approach is built for curative intent, not chronic management. It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation. View our full poster here 👉 www.graphtx.com/articles/aai...

graphtx.com

Graph Therapeutics - precision immunology

The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets. 🎯

FIM (Functional Immune Manifold) is Graph's platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.

100

Today's rheumatoid arthritis (RA) therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction. At IMMUNOLOGY2026, Graph's co-founder & VP Immunology Christophe Boudesco presented the latest results from our platform FIM. 🏗️ ⚙️

Graph @graphtx.bsky.social · 02/04/2026

Attending IMMUNOLOGY2026? Stop by the Parse x Graph happy hour to talk science & to celebrate our joint partnership to create one of the largest & most comprehensive immune cell perturbation atlases. 🧬🔍 📆 16 April 2026, 19:00 📍 Trillium Brewing Fort Point 🎟️ RSVP: lnkd.in/d7sbWbEA

Graph @graphtx.bsky.social · 24/03/2026

💡 Poster: Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets [no. 151] 📍 Computational and Systems Immunology I, Exhibit Hall 📅 16 April 2026, 11:30 - 12:30 💬 Presenting author: Christophe Boudesco

Graph @graphtx.bsky.social · 24/03/2026

Hey Boston, we’ll be attending #IMMUNOLOGY2026 from 16 - 19 April! Connect with us over our work in immune dysfunction mapping for next generation drug discovery in rheumatoid arthritis.

Graph @graphtx.bsky.social · 11/03/2026

🔔 Please arrive by 13:25. Representatives will be at the entrance to provide building access.

000

Graph @graphtx.bsky.social · 11/03/2026

Join us for a guest talk with @psl-schaefer.bsky.social (@saezlab.bsky.social, Uni Heidelberg)! 💬 Machine Learning for Cellular Perturbations at Scale: Current Capabilities, Limits, and Open Questions 📆 17 March 2026, 13:30 - 14:30 📍 LBI NetMed, Julius-Tandler-Platz 3, Top 5.1, 1090 Vienna

Graph @graphtx.bsky.social · 24/02/2026

Meet the team behind Graph and say hello to Rin Okumura, Senior Scientist! 🧗⛷️ With Rin on the team, we’re scaling lab-in-the-loop discovery by translating complex biology to high-throughput automated workflows. ➕✖️

Graph @graphtx.bsky.social · 30/01/2026

A tremendous thank you to the team at Bleed Design Studio for their fresh ideas and precise implementation of helping us visualize the complexity of our work!

Graph @graphtx.bsky.social · 30/01/2026

New look, same mission. 🧑‍🚀 🚀 We’re excited to debut our updated website that reflects who we are and the work we are doing at Graph: unafraid and boldly confronting the dynamic behavior of immune biology head on. Check it out 🌐 www.graphtx.com

Thanks to the organizers of this Keystone Symposia meeting! We’re already looking forward to the next one. ➕✖️

000

To better understand how immune cells jointly behave in a complex inflammatory environment, the Graph team profiled millions of primary-immune cells in a disease-relevant systemic inflammation condition, and identified numerous hits that affect inflammasome modulation in monocytes. 📊 💡

100

Focusing on the NLR-specific endpoint of endogenous ASC-speckling in sterile inflammation, we mapped systemic responses by using our platform for fast, patient-first I&I discovery. 🗺️ 📍

100

In our latest talk & poster presentation at the Keystone Autoimmunity & Autoinflammation symposium, Graph’s co-founder & CSO Bojan Vilagos presented our generalizable & scalable approach for discovering shared mechanisms across disease contexts. 🧬 ⚙️ Full poster here 👉 graphtx.com/inflammasome...

Together with Parse’s GigaLab technology that can profile hundreds of millions of cells and Graph’s lab-in-the-loop platform that can systematically select and test perturbations across a wide range of disease contexts, we are reshaping the future of AI-first drug discovery. ➕✖️

Immune-mediated & autoimmune diseases are notoriously difficult to model. By leveraging primary patient-derived cells rather than cell lines or animal models, this partnership allows the team at Graph to identify the most promising disease mechanisms, drug targets, & biomarkers early in discovery.

Parse Biosciences and Graph are partnering to create the world's most comprehensive immune cell perturbation atlas aimed at revealing immune system dysfunction for curative drug discovery. 🧬 🗺️ ➡️ Read more: www.parsebiosciences.com/news/parse-b...

140

000

Graph @graphtx.bsky.social · 15/01/2026

100

Fantastic panel at the Evotec Breakfast Reception in SF! Graph co-founder @gregvladimer.bsky.social shared insights alongside leaders from @isomorphiclabs.bsky.social & @medra-ai.bsky.social about how AI helps to unlock disease mechanisms & supports the development of future bio discoveries. 🚀

030

Graph @graphtx.bsky.social · 13/01/2026

Poster title: “Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets” 📍 Poster session 1 📅 20 January 2026 💬 Presenting author: Bojan Vilagos

Graph @graphtx.bsky.social · 13/01/2026

🏔️ Hey Colorado, we’ll be up in the Rockies from 19 - 22 January 2026 for the Autoimmunity & Autoinflammation symposium! We’re looking forward to showcasing our approach of using advanced imaging & data modeling to find clinically-relevant targets & pathways for immune diseases in our latest poster.

Graph @graphtx.bsky.social · 17/12/2025

🌊 ⛵ Hey San Francisco, on 13 January 2026 adjacent to the 44th Annual JPM Healthcare Conference, Graph’s co-founder and CEO Greg Vladimer will be speaking on Evotec's panel “Precision at Scale: AI’s impact on Drug Discovery." Let us know if you are in San Francisco and let’s talk techbio!

030

Graph @graphtx.bsky.social · 10/12/2025

Just last week, we had a group retreat (aka Graph Con) to a mountain hut in the Alps 🇦🇹. We spent some time honing our cooking skills, enjoying the wintry landscape, and forging our 2026 strategy around immune dysfunction mapping. We’re already energized for 2026, and we’re just getting started. 💫

021

Graph @graphtx.bsky.social · 26/11/2025

Thank you to everyone who attended our AI x Bio meetup last week in Berlin! We had a great time catching up with old friends and making new connections. 🪩 🕺 👏 A huge thank you to all of our cohosts, including @Merantix AI Campus, Merantix Capital, CytoData, and @techbio.bsky.social support!

Graph @graphtx.bsky.social · 24/11/2025

What does it takes to build real prediction power for precision immunology? Hint: it's about mapping immune dysfunction and scaling what's relevant. ➡️ Have a look at what we're building at Graph: graphtx.substack.com/p/building-t...

graphtx.substack.com

Building the Data Foundation to Scale Precision Immunology

Towards context-conditioned foundation models of immune dysfunction

030

Graph @graphtx.bsky.social · 21/11/2025

Thanks to everyone who came by our poster session! If you missed us there or want to learn more, you can view our full poster online: graphtx.com/Graph_CytoDa...

Graph @graphtx.bsky.social · 21/11/2025

By using rheumatoid arthritis (RA) as a case study, the Graph team demonstrates a generalizable framework that can work in iterative cycles of lab experimentation and prediction, i.e. a lab-in-the-loop approach 🔁, to systematically understand mechanisms and drivers of the disease.